A technical help webinar was held for potential candidates of the next Discover of Funding Alternative (NOFO): Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required) . Nationwide Institute of Psychological Well being employees answered questions associated to this NOFO.
The aim of this NOFO is to help one scientific trial community to guage organic, digital, cognitive, and scientific final result measures in people at scientific excessive threat (CHR) for psychosis in Proof of Precept (PoP) trial(s) utilizing a pharmacological intervention. Distinctive drug growth instruments developed by AMP® SCZ initiative will probably be evaluated within the PoP trial(s). The compound(s) chosen for testing by the AMP SCZ Steering Committee will have an effect on a pathophysiologically related mechanism and have the potential to provide a detectable sign on organic, digital, cognitive, or scientific final result measures inside a 12-16 week interval of research.
Learn the transcript.
Division of Translational Analysis
Jonathan Sabbagh, Ph.D.